越来越多的研究针对益生菌在疾病治疗中的作用进行。Kefir是一种安全、低成本的益生菌发酵牛奶饮品，在许多体外和动物研究中被研究，但人体疗效剂量或治疗时间的参数尚未确定。为对使用Kefir作为治疗剂的临床研究进行范围性回顾，并编制结果以支持和指导进一步研究。该回顾基于Joanna Briggs研究所的指导方针，包括涉及人类Kefir发酵牛奶效应的研究。使用KEFIR一词，在主要国际数据库中搜索英语、西班牙语或葡萄牙语的研究，直到2022年3月9日。共确定了4个数据库中的5835篇文章，其中44篇符合分析条件。研究领域包括代谢综合征和2型糖尿病、胃肠健康/疾病、孕产妇健康和儿科、牙科、肿瘤学、妇女和老年人健康以及皮肤学。研究限制较多，阻碍了结果的一般化。小样本量、方法学差异以及Kefir类型、剂量和治疗时间的差异阻碍了对其特定疾病益处的清晰结论。我们建议按体重以毫升为单位使用传统制备的标准治疗剂量，使日常消费更为可行。研究表明，Kefir对未患有严重疾病的人群是安全的。

Increasing research has been conducted on the role of probiotics in disease treatment. Kefir, a safe, low-cost probiotic fermented milk drink, has been investigated in many in vitro and animal studies, although parameters for human therapeutic dose or treatment time have not yet been determined. To perform a scoping review of clinical studies that have used kefir as a therapeutic agent, compiling the results for perspectives to support and direct further research. This review was based on Joanna Briggs Institute guidelines, including studies on the effects of kefir-fermented milk in humans. Using the term KEFIR, the main international databases were searched for studies published in English, Spanish, or Portuguese until March 9, 2022. A total of 5835 articles were identified in the 4 databases, with 44 eligible for analysis. The research areas were classified as metabolic syndrome and type 2 diabetes, gastrointestinal health/disorders, maternal/child health and pediatrics, dentistry, oncology, women's and geriatric health, and dermatology. The many study limitations hampered generalization of the results. The small sample sizes, methodological variation, and differences in kefir types, dosage, and treatment duration prevented clear conclusions about its benefits for specific diseases. We suggest using a standard therapeutic dose of traditionally prepared kefir in milliliters according to body weight, making routine consumption more feasible. The studies showed that kefir is safe for people without serious illnesses.